New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Trial Watch: Toll-like receptor agonists in cancer immunotherapy ONCOIMMUNOLOGY Smith, M., Garcia-Martinez, E., Pitter, M. R., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L. 2018; 7 (12): e1526250Abstract
Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.
View details for DOI 10.1080/2162402X.2018.1526250
View details for Web of Science ID 000450462000033
View details for PubMedID 30524908
View details for PubMedCentralID PMC6279325